BCR and chronic myelogenous leukemia, BCR-ABL1 positive: The safety of avasimibe and ability to re-sensitise TKI resistant BCR::ABL1+ cell lines to TKI treatment, indicates that targeting cholesterol storage may serve as an effective combination treatment strategy in TKI resistant CML patients.